Gedeon Richter has earned a raised outlook, and the nine-month numbers show why. Pharma revenues at constant exchange rates grew 11.7% in the first nine months of 2026, while reported pharma revenues rose only 2.6% to HUF 686.5bn. The gap is mostly currency: the report cites roughly 9 percentage points of headwind. Investors who look only at the reported figure will undervalue what the company actually delivered.

The profit story is stronger still. Clean EBIT for pharma rose 25% at constant exchange rates over the nine months, and reported Clean EBIT increased 8% to HUF 229.9bn. The company credits its BIO division approaching breakeven, continued strength in cariprazine, and lower operating expenses from efficiency initiatives. Those are operating explanations rather than accounting ones, which makes them more durable. Net profit attributable to the owners reached HUF 174.9bn, up 7.1%, and free cash flow before mergers and acquisitions hit a record HUF 223bn, up 12%.

The product detail reinforces the case. CNS segment revenues grew 19% at constant exchange rates, with Vraylar sales at AbbVie reaching $3.04bn, up 17%, and Reagila sales jumping 37%. Women's Healthcare sales rose 11% over nine months and accelerated to 19% in the third quarter, led by Ryeqo, Lenzetto, and Drovelis. BIO revenues climbed 35%, supported by biosimilars and CDMO work. A company growing across several franchises is less exposed to a single product's fate.

Management's response has been to lift 2026 guidance to above 10% revenue growth at constant exchange rates and to high-teens growth in Clean EBIT. That is a reasonable reading of the year so far, though the guidance is only as good as the assumptions behind it, and the report does not spell those out in detail. Shareholders should press for clarity on how much of the third-quarter acceleration is expected to persist into next year.

Gedeon Richter should keep reporting its results at constant exchange rates alongside the reported figures, as it does here. Currency swings will continue to distort the headline numbers, and a clear, consistent bridge between the two is the fastest way to earn credibility with the market. On this evidence, the upgrade is earned.